Fox Chase's Hormoz Ehya Inducted as President of the American Society of Cytopathology
PHILADELPHIA (December 9, 2009) – Hormoz Ehya, MD - Chief, Cytopathology, Pathology, Chief of Cytopathology at Fox Chase Cancer Center, was inducted as President of the American Society of Cytopathology (ASC) in November during the organizations 57th Annual Scientific Meeting in Denver.
Dr. Ehya has been an active member of the ASC since 1980 and has served on the Executive Board over the past six years. He was elected as Vice-President of ASC in 2007. His contributions to the Society include serving as past chair of the Scientific Program Committee, strengthening the conflict of interest policies, and fostering ties between the ASC and the international cytology community. He received the 1980 Warren Lang Resident Physician Award and the 1998 President's Award of the ASC.
After completing his pathology residency at the University of Mississippi Medical Center and cytopathology fellowship at Memorial Sloan-Kettering Cancer Center, Dr. Ehya pursued an academic career that has included cytopathology practice, teaching, administration and research. He serves on the Thyroid Practice Guidelines Panel of the National Comprehensive Cancer Network, Scientific Program Committee of the International Academy of Cytology and the editorial boards of major cytopathology journals.
The ASC, founded in 1951, is a distinguished national professional society of physicians, cytotechnologists and scientists who are dedicated to the detection and early diagnosis of nearly all forms of cancer. The ASC is the largest medical society solely devoted to recognizing cellular abnormalities in order to benefit patients. The majority of tests that the ASC Members interpret are Pap tests. The ASC's diverse membership of more than 3,000 individuals includes representatives from other countries who share a vision of education, research and continuous improvement in the standards and quality of patient care. The ASC is a unique society that provides a forum where physicians and cytotechnologists can interact and network with each other on both a personal
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute’s prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center’s nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427).